JP7181612B2 - アルカリ安定性免疫グロブリン結合タンパク質 - Google Patents

アルカリ安定性免疫グロブリン結合タンパク質 Download PDF

Info

Publication number
JP7181612B2
JP7181612B2 JP2019505354A JP2019505354A JP7181612B2 JP 7181612 B2 JP7181612 B2 JP 7181612B2 JP 2019505354 A JP2019505354 A JP 2019505354A JP 2019505354 A JP2019505354 A JP 2019505354A JP 7181612 B2 JP7181612 B2 JP 7181612B2
Authority
JP
Japan
Prior art keywords
binding
amino acid
protein
seq
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019505354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531055A (ja
JP2019531055A5 (enExample
Inventor
ニック，ポール
フィードラー，エリク
ハウプツ，ウルリッヒ
メイシン，マレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navigo Proteins GmbH
Original Assignee
Navigo Proteins GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navigo Proteins GmbH filed Critical Navigo Proteins GmbH
Publication of JP2019531055A publication Critical patent/JP2019531055A/ja
Publication of JP2019531055A5 publication Critical patent/JP2019531055A5/ja
Priority to JP2022112299A priority Critical patent/JP2022160444A/ja
Application granted granted Critical
Publication of JP7181612B2 publication Critical patent/JP7181612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2221/00—Applications of separation devices
    • B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2019505354A 2016-08-11 2017-08-07 アルカリ安定性免疫グロブリン結合タンパク質 Active JP7181612B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022112299A JP2022160444A (ja) 2016-08-11 2022-07-13 アルカリ安定性免疫グロブリン結合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16183710 2016-08-11
EP16183710.9 2016-08-11
EP16205707 2016-12-21
EP16205707.9 2016-12-21
PCT/EP2017/069976 WO2018029157A1 (en) 2016-08-11 2017-08-07 Novel alkaline stable immunoglobulin-binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022112299A Division JP2022160444A (ja) 2016-08-11 2022-07-13 アルカリ安定性免疫グロブリン結合タンパク質

Publications (3)

Publication Number Publication Date
JP2019531055A JP2019531055A (ja) 2019-10-31
JP2019531055A5 JP2019531055A5 (enExample) 2020-08-13
JP7181612B2 true JP7181612B2 (ja) 2022-12-01

Family

ID=59631752

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019505354A Active JP7181612B2 (ja) 2016-08-11 2017-08-07 アルカリ安定性免疫グロブリン結合タンパク質
JP2019507171A Active JP6951417B2 (ja) 2016-08-11 2017-08-07 アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用
JP2022112299A Pending JP2022160444A (ja) 2016-08-11 2022-07-13 アルカリ安定性免疫グロブリン結合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019507171A Active JP6951417B2 (ja) 2016-08-11 2017-08-07 アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用
JP2022112299A Pending JP2022160444A (ja) 2016-08-11 2022-07-13 アルカリ安定性免疫グロブリン結合タンパク質

Country Status (11)

Country Link
US (4) US11230576B2 (enExample)
EP (4) EP3497118B1 (enExample)
JP (3) JP7181612B2 (enExample)
KR (3) KR102573370B1 (enExample)
CN (4) CN109963864B (enExample)
AU (2) AU2017311541B2 (enExample)
CA (2) CA3031858A1 (enExample)
DK (1) DK3497117T5 (enExample)
LT (1) LT3497117T (enExample)
SG (1) SG11201901066UA (enExample)
WO (2) WO2018029157A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
CA2991812C (en) 2015-07-16 2024-02-13 Navigo Proteins Gmbh Immunoglobulin-binding proteins and their use in affinity purification
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CA3022751A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN109963864B (zh) * 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
EP3546476A1 (en) * 2018-03-26 2019-10-02 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
EP4491268A3 (en) * 2017-08-07 2025-04-09 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP4249097A3 (en) 2018-02-01 2024-01-10 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
JP7591284B2 (ja) * 2018-11-12 2024-11-28 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫グロブリンＦｃドメインに対する結合親和性を持たない新規三重らせんポリペプチド及び同ポリペプチドの使用
EP3650465A1 (en) 2018-11-12 2020-05-13 Navigo Proteins Gmbh Novel populations of polypeptides having a triple-helical structure
AU2020213921B2 (en) * 2019-02-01 2022-06-16 Navigo Proteins Gmbh Immunoglobulin binding proteins for affinity purification
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
JP7432813B2 (ja) * 2019-09-10 2024-02-19 東ソー株式会社 免疫グロブリン結合性タンパク質
CA3155432A1 (en) * 2019-12-17 2021-06-24 Navigo Proteins Gmbh Binding proteins for the enzyme acid alpha glucosidase (gaa) and uses thereof
WO2021165395A1 (en) * 2020-02-21 2021-08-26 Navigo Proteins Gmbh Affinity ligand for the soluble part of fibroblast growth factor receptor 3 (sfgfr3)
EP3875472A1 (en) * 2020-03-06 2021-09-08 Navigo Proteins Gmbh Novel immunoglobulin binding polypeptides
CA3183655A1 (en) * 2020-06-23 2021-12-30 Mathias KAHL Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
EP4132943B1 (en) * 2020-07-15 2024-05-29 Navigo Proteins Gmbh Immunoglobulin binding proteins for affinity purification
JP2023547340A (ja) * 2020-11-09 2023-11-10 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｉｉ型コラーゲン結合タンパク質
EP4001301A1 (en) * 2020-11-13 2022-05-25 Navigo Proteins Gmbh Binding protein for complement factor h (cfh)
EP4380955A1 (en) * 2021-08-06 2024-06-12 Roche Diagnostics GmbH Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
CN116675729A (zh) * 2021-12-21 2023-09-01 百林科(兰州)新材料有限公司 耐碱蛋白A变体去除样品中IgG抗体的应用
CN113999294B (zh) * 2021-12-30 2022-03-29 苏州纳微科技股份有限公司 免疫球蛋白结合蛋白及其应用
CN114409748A (zh) * 2022-01-28 2022-04-29 博格隆(浙江)生物技术有限公司 蛋白a的b结构域和z结构域突变体及其应用
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
KR20250112269A (ko) * 2022-12-16 2025-07-23 나피고 프로타인스 게엠베하 친화성 크로마토그래피를 위한 신규한 리간드
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
EP4541444A1 (en) * 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Fusion protein for affinity capture

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006304633A (ja) 2005-04-26 2006-11-09 Apro Life Science Institute Inc イムノグロブリン結合タンパク質
WO2012133349A1 (ja) 2011-03-25 2012-10-04 株式会社カネカ アフィニティー分離マトリックス用タンパク質
WO2016079033A1 (en) 2014-11-17 2016-05-26 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
DE69533102T2 (de) * 1994-07-21 2005-06-02 Aventis Pasteur Ltd., Toronto Analog von haemophilus hin47 mit verminderter protease aktivität
AU7142796A (en) 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
EP0985032B2 (en) 1997-05-28 2009-06-03 Discerna Limited Ribosome complexes as selection particles for in vitro display and evolution of proteins
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030045681A1 (en) 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
US6799121B2 (en) 2000-03-30 2004-09-28 York University Sequencing of peptides by mass spectrometry
US20110179531A1 (en) 2000-05-09 2011-07-21 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US20040043386A1 (en) 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
WO2005044845A2 (en) 2003-11-04 2005-05-19 Yale University Protein binding miniature proteins
WO2005059131A2 (en) 2003-12-11 2005-06-30 Yale University Protein binding miniature proteins and uses thereof
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
JP2008543278A (ja) 2005-05-11 2008-12-04 フィロゲン エスピーエー フィブロネクチンｅｄ−ｂに対する抗体ｌ１９とインターロイキン１２との融合タンパク質
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
EP1945767B1 (de) 2005-11-09 2010-04-07 MorphoSys AG Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
ES2606490T3 (es) 2006-05-08 2017-03-24 Philogen S.P.A. Citocinas dirigidas por anticuerpos para terapia
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
CN101522278B (zh) * 2006-09-29 2016-08-10 通用电气健康护理生物科学股份公司 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
CA2731388C (en) 2008-07-21 2018-05-01 Apogenix Gmbh Tnfsf single chain molecules
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
CN102753568B (zh) 2009-12-14 2014-08-20 塞尔蛋白质股份有限公司 用于识别具有结合配体能力的异源多聚体修饰的泛素蛋白质的方法
KR101893225B1 (ko) * 2010-03-24 2018-08-29 가부시키가이샤 가네카 면역 글로불린에 특이적으로 결합하는 단백질 및 면역 글로불린 결합성의 친화성 리간드
SG10201604559TA (en) * 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US9492572B2 (en) 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
WO2013186329A1 (en) 2012-06-13 2013-12-19 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
AU2013318928A1 (en) 2012-09-21 2015-04-09 Kaneka Corporation Protein ligand for affinity isolation matrix
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
US9896486B2 (en) * 2013-07-10 2018-02-20 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
US20180030140A1 (en) 2015-02-06 2018-02-01 Navigo Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
CA2991812C (en) 2015-07-16 2024-02-13 Navigo Proteins Gmbh Immunoglobulin-binding proteins and their use in affinity purification
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CA2991814A1 (en) 2015-07-20 2017-01-26 Navigo Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
CA3022751A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN109963864B (zh) 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
EP4491268A3 (en) 2017-08-07 2025-04-09 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP4249097A3 (en) 2018-02-01 2024-01-10 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006304633A (ja) 2005-04-26 2006-11-09 Apro Life Science Institute Inc イムノグロブリン結合タンパク質
WO2012133349A1 (ja) 2011-03-25 2012-10-04 株式会社カネカ アフィニティー分離マトリックス用タンパク質
WO2016079033A1 (en) 2014-11-17 2016-05-26 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides

Also Published As

Publication number Publication date
KR102573370B1 (ko) 2023-09-01
WO2018029157A1 (en) 2018-02-15
US20210206815A1 (en) 2021-07-08
CN109963864B (zh) 2024-01-02
CN117736281A (zh) 2024-03-22
KR20190038560A (ko) 2019-04-08
JP2019531055A (ja) 2019-10-31
DK3497117T5 (da) 2024-09-02
CN109963864A (zh) 2019-07-02
EP3497117B1 (en) 2024-01-24
AU2017311542A1 (en) 2019-02-07
CA3030208A1 (en) 2018-02-15
EP4177260A1 (en) 2023-05-10
JP2022160444A (ja) 2022-10-19
AU2017311542B2 (en) 2021-06-24
DK3497117T3 (da) 2024-04-22
US11230576B2 (en) 2022-01-25
US20190177376A1 (en) 2019-06-13
EP3497118B1 (en) 2022-09-14
CN116333065A (zh) 2023-06-27
SG11201901066UA (en) 2019-03-28
US20190300568A1 (en) 2019-10-03
CN109476712B (zh) 2022-08-02
US20250051400A1 (en) 2025-02-13
AU2017311541B2 (en) 2020-08-13
JP2019527715A (ja) 2019-10-03
EP3497117A1 (en) 2019-06-19
EP4324840A3 (en) 2024-04-24
EP3497118A1 (en) 2019-06-19
AU2017311541A1 (en) 2019-02-21
US11014967B2 (en) 2021-05-25
CN109476712A (zh) 2019-03-15
WO2018029158A1 (en) 2018-02-15
KR20190044059A (ko) 2019-04-29
KR102578256B1 (ko) 2023-09-15
LT3497117T (lt) 2024-05-10
CA3031858A1 (en) 2018-02-15
KR20230133943A (ko) 2023-09-19
EP4324840A2 (en) 2024-02-21
JP6951417B2 (ja) 2021-10-20

Similar Documents

Publication Publication Date Title
JP7181612B2 (ja) アルカリ安定性免疫グロブリン結合タンパク質
EP3322721B1 (en) Novel immunoglobulin-binding proteins and their use in affinity purification
US11548929B2 (en) Fc binding proteins with cysteine in the c-terminal helical region
JP7355729B2 (ja) Ｃ末端ヘリカル領域にシステインを有するｆｃ結合タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220713

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220713

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220818

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221111

R150 Certificate of patent or registration of utility model

Ref document number: 7181612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250